GENOVIS: COMMUNIQUÉ FROM ANNUAL GENERAL MEETING FOR GENOVIS AB (PUBL) March 20, 2012

GENOVIS: COMMUNIQUÉ FROM ANNUAL GENERAL MEETING FOR GENOVIS AB (PUBL) March 20,
2012

The following decisions were adopted at the Annual General Meeting:

The balance sheet and income statement were ratified.

The Board of Directors and the CEO were discharged from liability.

The Board shall consist of seven ordinary members with no alternates until the
next Annual General Meeting.

Ebba Åsly Fåhraeus, Thomas Laurell, Kenth Petersson, Jacob Engellau and Carina
Schmidt, were re-elected as Board members. Peter Ragnarsson and Erik Walldén was
elected new Board members.

Nicklas Gerhardsson has declined re-election.

Ebba Åsly Fåhraeus was elected as Chairman of the Board.

About Peter Ragnarsson

Peter Ragnarsson (b. 1963) is active as CEO of LMK Ventures AB. Ragnarsson was
previously CEO of Axis AB, Bell Group Plc and AudioDev AB. In addition, he has
also held various positions at Niscayah Group AB, Securitas AB, Arjo BV and SET
Revisionsbyrå. Rgnarsson is a board member of LMK Ventures AB, Hotel
Kungsträdgården AB, Generic Sweden AB, Nocroc Ventures AB, Gullberg & Jansson
AB, Aqilles Invest AB and LMK Hotels & Real Estate AB.

About Erik Walldén

Erik Walldén (b. 1949) is CEO of the Swedish company Gyros, which is active in
miniaturization of laboratory processes for protein analysis. Walldén was
previously CEO of the Swedish biotech company Affibody Holding, Biacore
International and Pyrosequencing. Walldén participated in the establishment of
and has been active at the following companies: PerSeptive Biosystems Inc.,
Pharmacia Biosensor and Pharmacia Biotech. Walldén is Vice Chairman of the Board
of Exiqon A/S, Chairman of SwedenBIO Business & Finance Working Group and board
member for Tecan Group Ltd.

A Nominating Committee shall be formed and consist of representatives of the
four largest shareholders at September 30, 2012, who are not members of the
Board.

Guidelines for remuneration for the CEO and other leading employees were
ratified in accordance with the Board’s proposal.

The Annual General Meeting resolved to reduce the company's share capital by
24,925,363.2 SEK and change sections 4 of the Articles of Association concerning
share capital and number of shares. The share capital shall comprise at the
lowest two million four hundred thousand (2 400 000) SEK and at the highest nine
million six hundred thousand (9 600 000) SEK.

The Annual General Meeting resolved to change sections 5. The number of shares
shall be at the lowest six million (6 000 000) and at the highest twenty-four
million (24 000 000).

The AGM decided that the number of shares shall be reduced by shares added up
1:10, which means that 10 shares are consolidated into one share.

The record date for the reverse split will be, April 10, 2012.

The AGM decided upon a new share issue with preemptive rights for current
shareholders, at which two existing shares give right to the subscription of one
new share at issue price of SEK 3:50 per share. The share capital will at the
most rise by SEK 1,384,742.4 by the issuing of new shares to a maximum of
3,461,856 at full subscription.

Timetable for new issue

April 16, 2012, Last trading day for Genovis share, including subscription
rights for new issue.

April 19, 2012, Record date for participation in the new issue; shareholders
registered in Genovis’ share register on this day receive subscription rights
for participation in the new issue.

April 25 – May 10, 2012, Subscription period. Subscription with preferential
rights through cash payment during the subscription period. Shareholders may
report their intention to subscribe throughout the subscription period.   

The AGM decided upon a share issue directed to LMK Ventures AB.The share capital
will at the most rise by SEK 580,000 by the issuing of new shares to a maximum
of 1,450,000 at full subscription. Allocation shall be made on condition that
the new share issue in is fully subscribed. The Board allocates the shares in
the rights issue within the maximum amount and the issue price will be SEK 3.50
in compliance with the rights issue.

The AGM decided to grant the Board authorization, for a period that does not
extend past the date of the next Annual General Meeting, on one or several
occasions, with or without pre-emptive rights for shareholders, to resolve on
the issue of new shares, convertibles or subscription options. It should also be
possible to make such an issue resolution stipulating cash payment and/or
stipulating payment in kind or set-off or otherwise with conditions. The issue
price for the new shares shall, in each instance, be set as close as possible to
the market price of the Company’s share. As a result of this authorization,
share capital could increase by a maximum of SEK 1,600,000 through the issuance
of 4,000,000 new shares at full subsciption.

For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel:
4646 -101235 sarah.fredriksson@genovis.com